Eledon制药公司计划提供库存和授权书,以资助开发用于肾移植、乙型肝移植和ALS的药物。 Eledon Pharmaceuticals plans a stock and warrant offering to fund development of its drug for kidney transplants, xenotransplantation, and ALS.

埃利登制药公司 (ELDN) 在2025年11月11日宣布,拟议公开发行普通股和预先资助的证券,收益将用于支持其主要药物特戈普鲁巴特的临床开发,用于移植,异种移植和ALS. Eledon Pharmaceuticals (ELDN) announced on November 11, 2025, a proposed public offering of common stock and pre-funded warrants, with proceeds to support clinical development of its lead drug, tegoprubart, for kidney transplantation, xenotransplantation, and ALS. 由Leerink Partners和Cantor Fitzgerald管理的提议可能包括15%的概括选项。 The offering, managed by Leerink Partners and Cantor Fitzgerald, may include a 15% overallotment option. 它须服从市场条件和监管批准,不能保证时机或完成。 It is subject to market conditions and regulatory approval, with no guarantee of timing or completion. 通过SEC网站提供初步招股说明书补充. A preliminary prospectus supplement is available via the SEC’s website.